---
title: "Fenofibrate - Hyperlipidemia"
sidebar: mydoc_sidebar
permalink: db01039-mesh-d006949-1.html
toc: false 
---


Path ID: `DB01039_MESH_D006949_1`
{% include image.html url="images/db01039-mesh-d006949-1.png" file="db01039-mesh-d006949-1.png" alt="db01039-mesh-d006949-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D011345">MESH:D011345 </a> | Fenofibrate | Drug |
| <a href="https://identifiers.org/MESH:C006012">MESH:C006012 </a> | Fenofibric acid | Drug |
| <a href="https://identifiers.org/UniProt:Q07869">UniProt:Q07869 </a> | Peroxisome proliferator-activated receptor alpha | Protein |
| <a href="https://identifiers.org/UniProt:P06858">UniProt:P06858 </a> | Lipoprotein lipase | Protein |
| <a href="https://identifiers.org/GO:0016042">GO:0016042 </a> | Lipid catabolic process | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D014280">MESH:D014280 </a> | Triglycerides | ChemicalSubstance |
| <a href="https://identifiers.org/MESH:D008075">MESH:D008075 </a> | Lipoproteins, HDL | ChemicalSubstance |
| <a href="https://identifiers.org/HP:0003124">HP:0003124 </a> | Hypercholesterolemia | PhenotypicFeature |
| <a href="https://identifiers.org/UniProt:P02656">UniProt:P02656 </a> | Apolipoprotein C-III | Protein |
| <a href="https://identifiers.org/GO:0006635">GO:0006635 </a> | Fatty acid beta-oxidation | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D015243">MESH:D015243 </a> | Cholesterol, VLDL | ChemicalSubstance |
| <a href="https://identifiers.org/MESH:D006949">MESH:D006949 </a> | Hyperlipidemia | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Fenofibrate | HAS METABOLITE | Fenofibric Acid |
| Fenofibric Acid | INCREASES ACTIVITY OF | Peroxisome Proliferator-Activated Receptor Alpha |
| Peroxisome Proliferator-Activated Receptor Alpha | INCREASES ACTIVITY OF | Lipoprotein Lipase |
| Peroxisome Proliferator-Activated Receptor Alpha | INCREASES ABUNDANCE OF | Lipoproteins, Hdl |
| Peroxisome Proliferator-Activated Receptor Alpha | DECREASES ACTIVITY OF | Apolipoprotein C-Iii |
| Peroxisome Proliferator-Activated Receptor Alpha | POSITIVELY REGULATES | Fatty Acid Beta-Oxidation |
| Peroxisome Proliferator-Activated Receptor Alpha | DECREASES ABUNDANCE OF | Cholesterol, Vldl |
| Lipoprotein Lipase | POSITIVELY REGULATES | Lipid Catabolic Process |
| Lipid Catabolic Process | DECREASES ABUNDANCE OF | Triglycerides |
| Lipoproteins, Hdl | NEGATIVELY CORRELATED WITH | Hypercholesterolemia |
| Hypercholesterolemia | POSITIVELY CORRELATED WITH | Hyperlipidemia |
| Apolipoprotein C-Iii | DECREASES ACTIVITY OF | Lipoprotein Lipase |
| Fatty Acid Beta-Oxidation | DECREASES ABUNDANCE OF | Triglycerides |
| Triglycerides | POSITIVELY CORRELATED WITH | Hyperlipidemia |
| Cholesterol, Vldl | POSITIVELY CORRELATED WITH | Hyperlipidemia |
|---------|-----------|---------|

Comment: Fenofibrate is pharmacologically inactive prodrug which undergoes rapid hydrolysis at the ester bond to form the active metabolite fenofibric acid.

Reference: 
  - [https://go.drugbank.com/drugs/DB01039#BE0000071](https://go.drugbank.com/drugs/DB01039#BE0000071)
  - [https://pubmed.ncbi.nlm.nih.gov/29760790/](https://pubmed.ncbi.nlm.nih.gov/29760790/)
